PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33616643-2	2021	OBJECTIVE: To evaluate efficacy and safety of avexitide [exendin(9-39)], a GLP-1 antagonist, for treatment of PBH.	exendin (9-39)	46-55	glucagon like peptide 1 receptor	Homo sapiens	75-80
33616643-2	2021	OBJECTIVE: To evaluate efficacy and safety of avexitide [exendin(9-39)], a GLP-1 antagonist, for treatment of PBH.	exendin (9-39)	57-70	glucagon like peptide 1 receptor	Homo sapiens	75-80
33616643-8	2021	RESULTS: Compared to placebo, avexitide 30 mg BID and 60 mg QD raised the glucose nadir by 21% (p=0.001) and 26% (p=0.0002) and lowered the insulin peak by 23% (p=0.029) and 21% (p=0.042), corresponding to 50% and 75% fewer participants requiring rescue during MMTT, respectively.	exendin (9-39)	30-39	BH3 interacting domain death agonist	Homo sapiens	46-49
33616643-8	2021	RESULTS: Compared to placebo, avexitide 30 mg BID and 60 mg QD raised the glucose nadir by 21% (p=0.001) and 26% (p=0.0002) and lowered the insulin peak by 23% (p=0.029) and 21% (p=0.042), corresponding to 50% and 75% fewer participants requiring rescue during MMTT, respectively.	exendin (9-39)	30-39	insulin	Homo sapiens	140-147
33289685-7	2021	CTSS retained its positive effects on glycemic control in mice injected the GLP-1 receptor antagonist exendin (9-39) amide.	exendin (9-39)	102-122	cathepsin S	Mus musculus	0-4
33289685-7	2021	CTSS retained its positive effects on glycemic control in mice injected the GLP-1 receptor antagonist exendin (9-39) amide.	exendin (9-39)	102-122	glucagon-like peptide 1 receptor	Mus musculus	76-90
33043402-9	2021	Exogenous glucagon had no effect on somatostatin secretion in Gcgr-/- mice, and a reduced effect when combined with the GLP-1 receptor antagonist exendin 9-39.	exendin (9-39)	146-158	glucagon-like peptide 1 receptor	Mus musculus	120-134
33172827-2	2021	Glucagon (1, 3 or 10 mug/kg), the GLP-1 receptor antagonist exendin 9-39 (30 nmol/kg), glucose (0.35 g/kg) or the incretin hormone glucose-dependent insulinotropic polypeptide (GIP; 3 nmol/kg) was injected intravenously or glucose (75 mg) was given orally through gavage.	exendin (9-39)	60-72	glucagon-like peptide 1 receptor	Mus musculus	34-48
32250530-10	2020	CONCLUSIONS: In patients with PBH, BID administration of SC avexitide effectively raised the glucose nadir and prevented severe hypoglycemia requiring rescue intervention.	exendin (9-39)	60-69	BH3 interacting domain death agonist	Homo sapiens	35-38
33017220-8	2020	In additional experiments, female mice, which are protected from acute olanzapine-induced hyperglycemia, displayed hyperglycemia, increases in glucagon and reductions in insulin when treated with olanzapine and the GLP1 receptor antagonist Exendin 9-39 (5 ug, IP) compared to olanzapine treatment alone.	exendin (9-39)	240-252	glucagon-like peptide 1 receptor	Mus musculus	215-228
32855719-3	2020	For this purpose, male Sprague-Dawley rats underwent sham surgery or left anterior descending artery ligation prior to being treated with saline/exendin-4/exendin-4 plus exendin9-39 (an antagonist of GLP-1 receptor) for 4 weeks.	exendin (9-39)	170-181	glucagon-like peptide 1 receptor	Rattus norvegicus	200-214
34356351-5	2021	Acute intracerebroventricular treatment with exendin-3(9-39)amide was used for pharmacological inhibition of brain GLP-1R in the control and STZ-icv rats, and oxidative stress was assessed in plasma, duodenum and ileum.	exendin (9-39)	45-65	glucagon-like peptide 1 receptor	Rattus norvegicus	115-121
32390511-11	2020	The GLP-1 receptor antagonist exendin 9-39 inhibited relaxation, and GLP-1(9-36)amide had no vasodilatory effect.	exendin (9-39)	30-42	glucagon-like peptide 1 receptor	Mus musculus	4-18
32390511-11	2020	The GLP-1 receptor antagonist exendin 9-39 inhibited relaxation, and GLP-1(9-36)amide had no vasodilatory effect.	exendin (9-39)	30-42	glucagon	Mus musculus	4-9
31328363-5	2019	During duodenal lipid infusion, participants received the GLP-1 antagonist exendin 9-39 or placebo.	exendin (9-39)	75-87	glucagon	Homo sapiens	58-63
21453734-5	2011	The mRNA expression of MyHC I and 2A as well as the percentage of MyHC I protein was remarkably increased in Ex-9-treated myotubes.	exendin (9-39)	109-113	myosin heavy chain 6	Homo sapiens	23-27
21453734-5	2011	The mRNA expression of MyHC I and 2A as well as the percentage of MyHC I protein was remarkably increased in Ex-9-treated myotubes.	exendin (9-39)	109-113	myosin heavy chain 6	Homo sapiens	66-70
32573108-9	2020	Nevertheless, treatment with exendin9-39, a GLP-1R inhibitor, remarkably reversed the protective effect of sitagliptin.	exendin (9-39)	29-40	glucagon-like peptide 1 receptor	Rattus norvegicus	44-50
32388229-8	2020	Finally, GLP-1R antagonist, exendin-3 (9-39) amide (Ex9), infused into the NTS differentially altered the ability of systemic-Ex4 to suppress the various behaviors of the sexual interaction chain, indicating that GLP-1R within the NTS is one of many sub-regions contributing to the GLP-1 dependent sexual behavior link.	exendin (9-39)	28-50	glucagon-like peptide 1 receptor	Mus musculus	9-15
32388229-8	2020	Finally, GLP-1R antagonist, exendin-3 (9-39) amide (Ex9), infused into the NTS differentially altered the ability of systemic-Ex4 to suppress the various behaviors of the sexual interaction chain, indicating that GLP-1R within the NTS is one of many sub-regions contributing to the GLP-1 dependent sexual behavior link.	exendin (9-39)	28-50	glucagon-like peptide 1 receptor	Mus musculus	213-219
32388229-8	2020	Finally, GLP-1R antagonist, exendin-3 (9-39) amide (Ex9), infused into the NTS differentially altered the ability of systemic-Ex4 to suppress the various behaviors of the sexual interaction chain, indicating that GLP-1R within the NTS is one of many sub-regions contributing to the GLP-1 dependent sexual behavior link.	exendin (9-39)	28-50	glucagon	Mus musculus	9-14
32361558-14	2020	Expressions of insulin and PDX1 in ductal cells could be blocked by exendin9-39, or beta-catenin inhibitor ICG001, or JAK2 inhibitor AG490.	exendin (9-39)	68-79	pancreatic and duodenal homeobox 1	Mus musculus	27-31
30976983-9	2019	Infusion of the GLP-1 receptor antagonist exendin 9-39 in recently operated asymptomatic post-RYGB did not alter FGF-19 levels after mixed meal.	exendin (9-39)	42-54	glucagon like peptide 1 receptor	Homo sapiens	16-30
30358871-5	2019	During enteral lipid infusion, participants received the GLP-1 antagonist exendin 9-39 or placebo.	exendin (9-39)	74-86	glucagon	Homo sapiens	57-62
34943934-13	2021	Treatment with Exendin9-39, a GLP-1R inhibitor, could abrogate the protective activity of GEN.	exendin (9-39)	15-26	glucagon-like peptide 1 receptor	Mus musculus	30-36